MedTrace Logo

Safety and Efficacy of MBF-118 in Patients with Crohn Disease

NCT05940558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-03-03

No results posted yet for this study

Summary

This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-118 oral treatment during 28 days in Crohn's disease patients on top of standard of care.

Conditions

  • Crohn Disease

Interventions

DRUG

MBF-118 oral capsules

MBF-118 oral capsules PPAR gamma receptor partial agonist

Sponsors & Collaborators

  • Medibiofarma S.L.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2024-09-10
Completion
2024-09-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940558 on ClinicalTrials.gov